Continued Paroxetine CR — Competitive Intelligence Brief

Continued Paroxetine CR (Continued Paroxetine CR) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Selective serotonin reuptake inhibitor (SSRI). Area: Psychiatry / Mental Health.

marketed Selective serotonin reuptake inhibitor (SSRI) Serotonin transporter (SERT) Psychiatry / Mental Health Small molecule

Target snapshot

Continued Paroxetine CR (Continued Paroxetine CR) — Massachusetts General Hospital. Paroxetine CR is a selective serotonin reuptake inhibitor (SSRI) that increases serotonin availability in the brain by blocking its reuptake at the synaptic cleft.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Continued Paroxetine CR TARGET	Continued Paroxetine CR	Massachusetts General Hospital	marketed	Selective serotonin reuptake inhibitor (SSRI)	Serotonin transporter (SERT)
Lexapro	escitalopram	Generic (originally Lundbeck/Forest)	marketed	Selective Serotonin Reuptake Inhibitor (SSRI)	Serotonin (5-HT) reuptake transporter	2002-08-14
Prozac	fluoxetine	Eli Lilly and Company	marketed	Selective Serotonin Reuptake Inhibitor (SSRI)	Serotonin reuptake transporter	1987-12-29
Lexapro (escitalopram)	Lexapro (escitalopram)	St. Luke's-Roosevelt Hospital Center	marketed	Selective serotonin reuptake inhibitor (SSRI)	Serotonin transporter (SERT)
Zoloft tablets	Zoloft tablets	Pfizer's Upjohn has merged with Mylan to form Viatris Inc.	marketed	Selective serotonin reuptake inhibitor (SSRI)	Serotonin transporter (SERT)
Low severity group: Escitalopram	Low severity group: Escitalopram	University of Texas Southwestern Medical Center	marketed	Selective serotonin reuptake inhibitor (SSRI)	Serotonin transporter (SERT)
placebo + fluoxetine	placebo + fluoxetine	University of Florida	marketed	Selective serotonin reuptake inhibitor (SSRI)	Serotonin transporter (SERT)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Selective serotonin reuptake inhibitor (SSRI) class)

1. University of Texas Southwestern Medical Center · 3 drugs in this class
2. Johns Hopkins University · 2 drugs in this class
3. GlaxoSmithKline · 2 drugs in this class
4. Daiichi Sankyo Co., Ltd. · 1 drug in this class
5. Guangdong Provincial People's Hospital · 1 drug in this class
6. Janssen Research & Development, LLC · 1 drug in this class
7. Medical University of Vienna · 1 drug in this class
8. Massachusetts General Hospital · 1 drug in this class
9. Fundació Sant Joan de Déu · 1 drug in this class
10. Centre Hospitalier Universitaire Dijon · 1 drug in this class